AG1 unveils Next Gen, first major product upgrade for North America

US-based AG1 unveils its “most significant innovation” with the first major upgrade of its all-in-one supplement powder mix in 15 years. The AG1 Next Gen blend, which includes upgraded probiotics and added vitamins and minerals, is only available on the North American market. The company says the formula is clinically shown to close common nutrient gaps and support gut health. 

The company shares scientific support from four randomized, placebo-controlled human clinical trials with the launch. Moreover, AG1 has committed over US$20 million to continued research. 

Nutrition Insight discusses the reformulation process with AG1’s chief science and nutrition officer, Ralph Esposito, and CEO, Kat Cole. 

“Over the past decade, we have seen a boom in research in the nutrition and microbiome space,” says Esposito. “As we continued to see these changes, our in-house team of doctors, scientists, and researchers spanning microbiology, immunology, nutritional sciences, and integrative medicine identified key areas where we could integrate this research into the AG1 formula.”

He says that AG1 Next Gen marks the company’s “most significant innovation yet.” 

It features five clinically studied probiotic strains: Lactobacillus rhamnosus GG, L. acidophilus NCFM, Bifidobacterium lactis HN019, L. casei LC-11, and L. plantarum LP-115. In addition, the new formula includes an enhanced methylated B complex and new and increased vitamins and minerals. 

Cole adds: “We’ve committed over US$20 million to research over the next three years — including ongoing research and clinical trials for innovation, collaborations with accredited research universities for discovery research, and continuing to bolster our in-house team.”

Clinical research

The new formulation is supported by three double-blind, randomized, placebo-controlled human trials and one triple-blind trial. AG1 Next Gen demonstrated a positive impact on closing common nutrient gaps in all these trials. 

The triple-blind trial evaluated nutrient biomarkers and microbiome shifts in 105 healthy adults (ages 20–59) in 12 weeks. 

The new formulation is supported by three double-blind, randomized, placebo-controlled human trials and one triple-blind trial.The researchers conducted two double-blind, two-week crossover trials to assess nutrient gaps and microbiome shifts in active or healthy adults, with one group experiencing occasional gastrointestinal distress. The final double-blind, placebo-controlled crossover trial assessed nutrient gaps and bioavailability in healthy adults over eight hours. 

One of the studies found that the new blend increased key nutrient levels, including folate and vitamin C, within three months. The research also found that key nutrients were quickly and easily absorbed into the body. 

Three randomized trials showed that, on average, AG1 Next Gen increased healthy bacteria in the gut by over ten times. These trials included participants with varying baseline gut health, age, and activity levels. 

“In our clinical trials, not only did we see AG1 Next Gen fill nutrient gaps, but we saw this consistently across the four trials among various populations from healthy individuals to active individuals, along with improvements in various nutrient biomarkers,” stresses Esposito. 

“This helps reinforce that most people are experiencing nutrient gaps and that AG1 Next Gen is a clinically backed solution to help fill nutrient gaps for these essential nutrients.” 

Next steps

The company’s holistic wellness supplement is based on a foundational nutrition concept — prioritizing ingredient synergy and bioavailability, focusing on micro- and phytonutrients, combined with whole foods and biotics for gut health and overall well-being. 

Esposito says that AG1 Next Gen is designed to balance out declining nutrient density as most US diets lack nutrient diversity.Earlier this year, we discussed AG1’s focus on continuous formulation upgrades with Cole and Esposito. Over the years, the company has transitioned to methylated folate and vitamin B12 to improve bioavailability and added the adaptogen rhodiola to help boost energy and manage stress. 

Esposito says the company aims to formulate a comprehensive and effective supplement that “covers nutrient gaps, supports gut health, and provides bioavailable nutrients for easy absorption.” 

“We are learning from more research that most US diets lack nutrient diversity, and so AG1 Next Gen is designed to complement a healthy diet and balance out a decline in nutrient density found in modern food.” 

Cole highlights the company’s focus on innovation. “We’re committed to continuing to upgrade our foundational product for our customers based on the latest science and research, and we will continue to innovate products to address the varied needs of our customers.”